ACCESS Newswire
04 May 2021, 02:49 GMT+10
ROCKVILLE, MD / ACCESSWIRE / May 3, 2021 / The American Kidney Fund (AKF) today announced a webinar, Cystatin C: Its utility as an alternative for creatinine-based eGFR, to educate healthcare practitioners about the cystatin C testing option for kidney health and help them effectively communicate about testing options to patients. The webinar, sponsored by Gentian Diagnostics, will take place tomorrow, Tuesday, May 4, 2021 from 1 p.m. - 2:15 p.m. ET.
Cystatin C is a protein used as a biomarker for kidney function. When a healthcare practitioner suspects a patient may have decreased kidney function, a cystatin C test may be ordered to help assess how well the kidneys are filtering. Measurement of serum cystatin C is gaining a greater role in the estimation of kidney function, particularly as the kidney community considers moving away from the current race-based eGFR equation which depends on creatinine measurement.
"Cystatin C can play an important role in providing an unbiased estimate of kidney function so that every individual may receive personalized, appropriate and equitable care," said LaVarne A. Burton, AKF president and CEO. "With the support from Gentian Diagnostics, AKF is pleased to host a professional webinar to help educate prescribers and allied health professionals about the use of cystatin C to assess kidney function."
The webinar will feature panelists globally respected in their fields of study, including:
During this interactive webinar, the multidisciplinary panel of experts will delve into the utility of the cystatin C test in diagnosing kidney disease. They will discuss why cystatin C could help eliminate racial bias and improve precision in treatment; the importance of educating the nephrology community on cystatin C; situations in which measuring cystatin C may be clinically useful; and the effort to encourage laboratories to bring this testing in-house.
"The pandemic has highlighted the criticality of clinical diagnostics, and the potential value that can be unlocked by innovations contributing to diagnostic efficiency," said Dr. Hilja Ibert, CEO of Gentian Diagnostics. "Gentian is proud to partner with the American Kidney Fund on this important topic and help support their mission in fighting kidney disease."
About the American Kidney Fund
The American Kidney Fund (AKF) fights kidney disease on all fronts as the nation's leading kidney nonprofit. AKF works on behalf of the 37 million Americans living with kidney disease, and the millions more at risk, with an unmatched scope of programs that support people wherever they are in their fight against kidney disease-from prevention through transplant. With programs that address early detection, disease management, financial assistance, clinical research, innovation and advocacy, no kidney organization impacts more lives than AKF. AKF is one of the nation's top-rated nonprofits, investing 97 cents of every donated dollar in programs, and holds the highest 4-Star rating from Charity Navigator and the Platinum Seal of Transparency from GuideStar. For more information, please visit KidneyFund.org, or connect with us on Facebook, Twitter, Instagram and LinkedIn.
About Gentian
Gentian is a Norwegian diagnostics company that specializes in making novel biomarkers available on the Particle-Enhanced Turbidimetric Immunoassay (PETIA) platform. The company's first commercially available product, The Gentian Cystatin C assay, was launched in 2006 and FDA 510k cleared in 2008. Gentian has since established itself as a global leader in the manufacture of cystatin C assays with its method being one of the few used to evaluate the commutability of the IFCC reference standard. Gentian's current portfolio of diagnostic reagents spans areas of kidney disease, cardiac disease, inflammation, infection and veterinary medicine.
Contacts
Ben Shannon
[email protected]
Links
https://www.kidneyfund.org/training/webinars/cystatin-c.html
SOURCE: American Kidney Fund
Get a daily dose of Miami Mirror news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Miami Mirror.
More InformationNEW YORK, New York - U.S. stocks diverged on Wednesday for the second day in a row. The Standard and Poor's 500 hit a new all-time...
NEW YORK CITY, New York: The U.S. dollar continues to lose ground, weighed down by growing concerns over Washington's fiscal outlook...
KABUL, Afghanistan: Afghanistan, long associated with war and instability, is quietly trying to rebrand itself as a destination for...
SANTA CLARA, California: Executives at Nvidia have quietly been cashing in on the AI frenzy. According to a report by the Financial...
NEW YORK, New York - Global stock indices closed with divergent performances on Tuesday, as investors weighed corporate earnings, central...
TORONTO, Canada: Canadian Prime Minister Mark Carney announced late on June 29 that trade negotiations with the U.S. have recommenced...
ISTANBUL/PARIS/BRUSSELS: As searing temperatures blanket much of Europe, wildfires are erupting and evacuation orders are being issued...
VENICE, Italy: Over the weekend, hundreds of protesters marched through the narrow streets of Venice to voice their opposition to billionaire...
PARIS, France: France is taking stronger steps to reduce smoking. A new health rule announced on Saturday will soon ban smoking in...
WASHINGTON, DC - U.S. President Donald Trump on Tuesday claimed Elon Musk's success has been built on government subsidies. Without...
EVERGLADES, Florida: Over the weekend, a diverse coalition of environmental activists, Native American leaders, and residents gathered...
BEIJING, China: China's national soccer team may struggle to stir excitement, but its humanoid robots are drawing cheers — and not...